Oral Cancer News – Page 300 – The Oral Cancer Foundation News Archive

House bill curbs advertising, increases taxes on smokeless tobacco

Source: The Clackamas Review Author: News Team A vending display for Snus, a smokeless, spitless tobacco Camel first marketed in Portland and Austin, Texas. A new house bill would limit advertising for such products while increasing taxes on them. JIM CLARK / PAMPLIN MEDIA GROUP The bill also bans the practice of handing out samples The Oregon House today passed a bill that would require all smokeless tobacco products to adhere to federally mandated marketing restrictions placed on older existing brands in an effort to curb youth advertising campaigns. The legislation would also increase the tax on such products. The bill, co-sponsored by House Speaker Dave Hunt, D-Gladstone, came about partially as a response to the proliferation of smokeless tobacco products critics said targeted young customers. In 2006, Camel used the Portland region and Austin, Texas as test markets for its Snus smokeless tobacco. Smoking cessation advocates cried foul, saying the colorful ads with their rhyming slogans were designed to attract young people. The bill also prevents companies from handing out free samples of smokeless tobacco, something Rep. Carloyn Tomei, D-Milwaukie, said was happening everywhere from the streets of Portland to rodeos and fairs in eastern Oregon, particularly since Washington already has a ban. She introduced a similar bill earlier this year. “Oregon has become the place where they have campaigns for smokeless tobacco,” she said. “They’re handing out free Snus samples, and to whom did they hand it out? Not people my age; it’s the young ones.” The bill would [...]

Charlotte Parker2009-04-23T12:49:25-07:00April, 2009|Oral Cancer News|

Cancer risk of nicotine gum and lozenges higher than thought

Source: www.timesonline.co.uk Author: Mark Henderson Nicotine chewing gum, lozenges and inhalers designed to help people to give up smoking may have the potential to cause cancer, research has suggested. Scientists have discovered a link between mouth cancer and exposure to nicotine, which may indicate that using oral nicotine replacement therapies for long periods could contribute to a raised risk of the disease. A study funded by the Medical Research Council, led by Muy-Teck Teh, of Queen Mary, University of London, has found that the effects of a genetic mutation that is common in mouth cancer can be worsened by nicotine in the levels that are typically found in smoking cessation products. The results raise the prospect that nicotine, the addictive chemical in tobacco, may be more carcinogenic than had previously been appreciated. “Although we acknowledge the importance of encouraging people to quit smoking, our research suggests nicotine found in lozenges and chewing gums may increase the risk of mouth cancer,” Dr Teh said. “Smoking is of course far more dangerous, and people who are using nicotine replacement to give up should continue to use it and consult their general practitioners if they are concerned. The important message is not to overuse it, and to follow advice on the packet.” Most nicotine replacement products have labels advising people to cut down after three months of use and to stop completely after six months. Mouth cancer affects nearly 5,000 people each year in Britain and is usually linked to smoking, chewing tobacco [...]

Oral Cancer Foundation News Team - A2009-04-22T13:47:53-07:00April, 2009|Oral Cancer News|

Perioperative chemotherapy in patients with oral cancer

Source: Medline Authors: Rao RS, Parikh DM, Parikh HK, Bhansali MB, Deshmane VH, Fakih AR In the final report of a prospective, randomized controlled clinical trial, we report the results of using adjuvant perioperative chemotherapy in patients with oral cancer. Our study is based on the hypothesis of Goldie and Coldman. A total of 135 patients with alveolobuccal carcinoma, classified as clinically stage III and IV, were entered on the protocol. After a curative resection, they were randomized. The patients in the test arm of the study received methotrexate 50 mg/m2 on the 3rd, 10th, and 17th postoperative days. The patients in the control arm underwent observation. This analysis at 24 months showed a disease-free survival rate of 61% in the test arm versus 37% in the control arm, which is statistically highly significant (P < 0.01). Analysis of the recurrence pattern showed that recurrence at the primary site was dramatically reduced during the first 6 postoperative months (P = 0.002). Our study provided further clinical evidence in support of the concepts of Goldie and Coldman that the timing of chemotherapeutic drugs is critical for a successful end result.

Charlotte Parker2009-04-23T12:47:16-07:00April, 2009|Oral Cancer News|

Penn Dental School walks for oral cancer

Source: media.www.dailypennsylvanian.com Author: Jenny Chung Diagnosed as the cause of death for over 8,000 Americans annually, oral cancer is a disease that rarely garners the attention it deserves. But this year, Penn Dental School students are raising awareness with the first Oral Cancer Walk Philadelphia. Organized by the Oral Cancer Awareness Society, the walk is to be held tomorrow - regardless of weather conditions - beginning at 10 a.m. Participants will follow a 3.1-mile circular route that starts and finishes at the University's School of Dental Medicine at 240 S. 40th St. All participants are required to raise a minimum of $20 to benefit the Oral Cancer Foundation, while oral cancer survivors are invited to walk for free as honored guests. Refreshments and live entertainment will be provided along the Walk free of charge until 2 p.m. Complimentary oral screenings will also be offered from 10 a.m. onward. OCAS was founded last year by Penn Dental students Ann Layvey and Natalie Powell, who were "inspired to organize a charity event of their own" after attending a Penn Law fundraiser last year, according to the Web site. The Walk was coordinated through the combined efforts of over 40 students in five different subcommittees and boasts a logo designed by Penn Dental student Susana Porras. Thus far, the group has raised nearly $10,000 for the Oral Cancer Foundation from corporate sponsors and various organizations affiliated with the dental school. According to Oral Cancer Walk Philadelphia Head of Media Relations Michelle Han, the [...]

Oral Cancer Foundation News Team - A2009-04-17T12:35:28-07:00April, 2009|OCF In The News, Oral Cancer News|

Prognostic factors for survival after salvage reirradiation of head and neck cancer

Source: Journal of Clinical Oncology, Vol 27, No 12 (April 20), 2009: pp. 1983-1991 Authors: Tawee Tanvetyanon et al. Purpose: Patients who develop recurrent or new primary head and neck cancer in a previously irradiated site have poor prognosis. Reirradiation is a treatment option, although it is associated with substantial toxicities. We investigated potential prognostic factors, including comorbidity and pre-existing organ dysfunction, for survival after reirradiation. Methods: Institutional electronic records of patients treated with reirradiation between January 1998 and 2008 were reviewed. Comorbidity was assessed by Charlson index and Adult Comorbidity Evaluation-27 (ACE-27) grading. Organ dysfunction was defined as feeding tube dependency, functioning tracheostomy, or soft tissue defect. Results: There were 103 patients, including 46 patients who underwent salvage surgery before reirradiation. Median progression-free and overall survivals were 12.1 months (95% CI, 9.7 to 16.6) and 19.3 months (95% CI, 13.9 to 29.9), respectively. Significant comorbidity was present in 36% of patients by Charlson index and 24% by ACE-27. Baseline organ dysfunction was present in 37% of patients. Median overall survivals were 5.5 months among those with both organ dysfunction and comorbidity per Charlson index, and 4.9 months per ACE-27, compared with 59.6 and 44.2 months, respectively, among the patients with neither organ dysfunction nor comorbidity (P

Oral Cancer Foundation News Team - A2009-04-17T12:31:32-07:00April, 2009|Oral Cancer News|

Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck

Source: Journal of Clinical Oncology, Vol 27, No 12 (April 20), 2009: pp. 1992-1998 Authors: Pernille Lassen et al. Purpose: A subset of head and neck cancers is associated with the human papillomavirus (HPV). Viral infection is closely correlated with expression of p16INK4A in these tumors. We evaluated p16INK4A as a prognostic marker of treatment response and survival in a well-defined and prospectively collected cohort of patients treated solely with conventional radiotherapy in the Danish Head and Neck Cancer Group (DAHANCA) 5 trial. Patients and Methods: Immunohistochemical expression of p16INK4A was analyzed in pretreatment paraffin-embedded tumor blocks from 156 patients treated with conventional primary radiotherapy alone. The influence of p16INK4A status on locoregional tumor control, disease-specific survival, and overall survival after radiotherapy was evaluated. Results: p16INK4A positivity was found in 35 tumors (22%). Tumor-positivity for p16INK4A was significantly correlated with improved locoregional tumor control (5-year actuarial values 58% v 28%; P = .0005), improved disease-specific survival (72% v 34%; P = .0006), and improved overall survival (62% v 26%; P = .0003). In multivariate analysis, p16INK4A remained a strong independent prognostic factor for locoregional failure (hazard ratio [HR], 0.35; 95% CI, 0.19 to 0.64), disease-specific death (HR, 0.36; 95% CI, 0.20 to 0.64), and overall death (HR, 0.44; 95% CI, 0.28 to 0.68). Conclusion: Expression of p16INK4A has a major impact on treatment response and survival in patients with head and neck cancer treated with conventional radiotherapy. Authors: Pernille Lassen, Jesper G. Eriksen, Stephen Hamilton-Dutoit, Trine Tramm, Jan Alsner, Jens [...]

Oral Cancer Foundation News Team - A2009-04-17T12:04:53-07:00April, 2009|Oral Cancer News|

Guidelines needed for optimal vitamin D supplementation in cancer patients

Source: www.medscape.com Author: Roxanne Nelson A growing amount of research suggests that vitamin D may be beneficial to cancer patients. In addition, laboratory, ecologic, and epidemiologic studies have shown some evidence that higher levels of vitamin D might lower the risk for colon, breast, endometrial, and prostate cancers. But although the "evidence is intriguing," an editorial published online April 6 in the Journal of Clinical Oncology speculates about how oncologists should disseminate this information in clinical practice. Editorialist Pamela J. Goodwin, MD, from the Samuel Lunenfeld Research Institute, Mount Sinai Hospital and Princess Margaret Hospital, in Toronto, Ontario, offers some suggestions to oncologists who are being asked to advise their patients about whether they should take vitamin D supplements. She emphasizes that her suggestions are of an interim nature. "As results of ongoing and planned research become available, many unanswered questions will be resolved, and more definitive recommendations that can be embraced by oncologists will be forthcoming," she notes in her editorial. Low Levels Noted in Breast Cancer Patients Interest in vitamin D has risen exponentially, Dr. Goodwin explains. The total number of published studies relating to vitamin D more than doubled from 1990 to November 2008, articles relating to cancer and vitamin D nearly tripled, and those specifically relating to breast cancer and vitamin D increased almost 6-fold. The editorial was prompted by a report, published in the same issue of the Journal, that, at baseline, 74% of premenopausal women with breast cancer who received adjuvant chemotherapy and participated [...]

Oral Cancer Foundation News Team - A2009-04-17T11:53:20-07:00April, 2009|Oral Cancer News|

With anti-addiction pill, ‘no urge, no craving’

Source: CNN.com Author: Caleb Hellerman CENTRAL FALLS, Rhode Island (CNN) -- A no-frills bar called Goober's, just north of Providence, Rhode Island, is probably the last place you'd expect to find a debate over cutting-edge addiction therapy. But this is where Walter Kent, a retired mechanic, spends his Fridays. He helps in the kitchen and hangs out in the bar, catching up with old friends. Walter Kent talks to Dr. Sanjay Gupta about how the drug naltrexone has helped keep him sober. Most addiction specialists would call this playing with fire, or worse. That's because for more than 30 years, Kent was a hard-core alcoholic. His drinks of choice were Heineken beer and Jacob Ginger brandy, but anything with alcohol would do. "It's like a little kid wanting a piece of candy. You see it, you want the taste of it." He closes his eyes and sniffs the air, remembering the feeling. "You can be by yourself, and all of a sudden get even a hint of alcohol, just the smell of it, and say, 'Oh, I need a drink.' That sensation is not something you can get rid of." But today, Kent isn't tempted in the least. He says the credit goes to a prescription medication -- a pill called naltrexone. It's part of a new generation of anti-addiction drugs that may turn the world of rehab on its head. Dr. Mark Willenbring, who oversees scientific research at the National Institute on Alcoholism and Alcohol Abuse, says alcoholism has reached a [...]

Charlotte Parker2009-04-17T09:49:29-07:00April, 2009|Oral Cancer News|

Oral Cancer Foundation calls for FDA authority over tobacco marketers

Source: Author: The Oral Cancer Foundation today called for the U.S. Senate to grant the U.S. Food and Drug Administration (FDA) authority over tobacco products in response to the tobacco industry's most aggressive marketing campaign targeted at women and girls in over a decade. The U.S. House of Representatives voted to give the FDA such authority approximately two weeks ago. "The percentage of oral cancer patients represented by women has increased tremendously over the past four decades, and we believe the marketing efforts of the tobacco industry is a major causal factor," said Brian Hill, founder of the Oral Cancer Foundation. "Before Virginia Slims began aggressively targeting women in the 1960s, roughly one-in-ten oral cancer victims was female. Since then, the ratio has quintupled to one-in-two." Hill also noted that lung cancer surpassed breast cancer as the number one cancer killer of women in 1987, and that while overall cancer rates are declining for men and women, lung cancer is not declining among women. Moreover, smoking puts women and girls at greater risk of a wide range of other deadly diseases, including heart attacks, strokes and emphysema. Hill cited "Deadly in Pink: Big Tobacco Steps Up Its Targeting of Women and Girls," a comprehensive report recently issued by the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association, Robert Wood Johnson Foundation and Campaign for Tobacco-Free Kids. The report studied numerous tobacco marketing campaigns, images from which can be found at www.tobaccofreekids.org/deadlyinpink. "In reading this report, three [...]

Oral Cancer Foundation News Team - A2009-04-17T08:05:22-07:00April, 2009|OCF In The News, Oral Cancer News|

WHO issues position on vaccines

Source: africasciencenews.org Author: staff In accordance with its mandate to provide guidance to Member States on health policy matters, WHO has issued a series of regularly updated position papers on vaccines and vaccine combinations against diseases that have an international public health impact. These papers, which are concerned primarily with the use of vaccines in large-scale immunization programs, summarize essential background information on their respective diseases and vaccines, and conclude with the current WHO position concerning their use in the global context. The papers have been reviewed by a number of experts within and outside WHO and, since April 2006, they have been reviewed and endorsed by WHO’s Strategic Advisory Group of Experts (SAGE) on vaccines and immunization. The position papers are designed for use mainly by national public health officials and managers of immunization programs. However, they may also be of interest to international funding agencies, the vaccine manufacturing industry, the medical community, scientific media and the public. Genital HPV infections are primarily transmitted by sexual contact, predominantly but not exclusively through penetrative intercourse. HPVs are highly transmissible, and most sexually active men and women will acquire an HPV infection at some time in their lives. Whereas most HPV infections are transient and benign, persistent genital infection with certain viral genotypes can lead to the development of anogenital precancers and cancers. Currently, 2 HPV vaccines are widely marketed internationally. Using recombinant technology, both are prepared from purified L1 structural proteins that self-assemble to form HPV type-specific empty shells or [...]

Oral Cancer Foundation News Team - A2009-04-15T07:23:53-07:00April, 2009|Oral Cancer News|